| Cat.No. | Name | Information |
|---|---|---|
| M3517 | Lapatinib | Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
| M1802 | Lapatinib Ditosylate | Lapatinib Ditosylate (CAS 388082-78-8) is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). |
| M1749 | Gefitinib | Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
| M5621 | Erlotinib (CP-358774) | Erlotinib (CP-358774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| M1913 | Neratinib | Neratinib (HKI-272) is an orally available, irreversible inhibitor of Her 2 tyrosine kinase. |
| M1850 | WZ4002 | WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
| M1869 | Dacomitinib | Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. |
| M5307 | Afatinib dimaleate | Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. |
| M2424 | AZD9291 (Osimertinib) | Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. |
| M1677 | Afatinib (BIBW 2992) | Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| M45211 | ABSK112 | ABSK112 is a potentially best-in-class, orally active, selective EGFR Exon20ins inhibitor with better brain entry properties, higher selectivity against wild-type EGFR, and broader Exon20ins mutation coverage profile. |
| M45210 | ABK3376 | ABK3376 is a novel EGFR inhibitor for studies related to EGFR C797S mutant non-small cell lung cancer. |
| M43838 | Almonertinib mesylate | Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer. |
| M42115 | MAPK-IN-2 | MAPK-IN-2 is a potent MAPK inhibitor with antineoplastic activity. |
| M42100 | EGFR-IN-81 | EGFR-IN-81 is an EGFR inhibitor. |
| M42099 | EGFR-IN-85 | EGFR-IN-85 is an EGFR inhibitor. |
| M42098 | JGK-068S | JGK-068S is a potent EGFR inhibitor. |
| M42096 | EGFR mutant-IN-2 | EGFR mutant-IN-2 is an EGFR mutant inhibitor. |
| M42095 | EGFR-IN-88 | EGFR-IN-88 is an EGFR inhibitor (IC50: 87 nM). |
| M42094 | EGFR-IN-84 | EGFR-IN-84 is an EGFR inhibitor (IC50: 24 nM). |
| M42093 | EGFR-IN-87 | EGFR-IN-87 is a EGFR tyrosine kinase inhibitor. |
| M42092 | EGFR-IN-83 | EGFR-IN-83 is an EGFR inhibitor (IC50: 2.53 nM). |
| M42091 | EGFR/ErbB-2 inhibitor-1 | EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor. |
| M42090 | HER2-IN-13 | HER2-IN-13 is an HER2 inhibitor with an IC50 of 8 nM. |
| M42089 | HER2-IN-14 | HER2-IN-14 is an HER2 inhibitor with an IC50 of 18 nM. |
| M42088 | EGFR-IN-79 | EGFR-IN-79 is an EGFR inhibior with antitumor activity. |
| M42087 | BEBT-109 | BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. |
| M42086 | PROTAC EGFR degrader 8 | PROTAC EGFR degrader 8 (T-184) is a PROTAC EGFR degrader. |
| M42085 | Erbstatin | Erbstatin, a EGFR kinase inhibitor, possesses antineoplastic effect. |
| M42084 | Gefitinib N-oxide hydrochloride | Gefitinib N-oxide hydrochloride is the N-oxide derivative of Gefitinib. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
